Pfizer To Use Cash From Sale Of OTC Unit To J&J For Biotech, Specialty Deals
Executive Summary
Pfizer will use the cash gained through the sale of its consumer unit to Johnson & Johnson to make targeted specialty pharma and biotech acquisitions, the firm said following announcement of the deal June 26
You may also be interested in...
J&J Acquisitions Governed By Payback Potential, Despite Credit “Uncertainty”
Maintaining a stellar credit rating is not a constraint on how much Johnson & Johnson is willing to spend on acquisitions, Chief Financial Officer Dominic Caruso said during the company's April 15 first quarter earnings call
J&J Acquisitions Governed By Payback Potential, Despite Credit “Uncertainty”
Maintaining a stellar credit rating is not a constraint on how much Johnson & Johnson is willing to spend on acquisitions, Chief Financial Officer Dominic Caruso said during the company's April 15 first quarter earnings call
Spreading The Risk: Wyeth Seeks Many Partnerships, Rather Than A Few Buys
Wyeth is focusing on reaching partnering deals for early stage agents rather than acquisitions to mitigate the high risk associated with such compounds, CEO Robert Essner said Jan. 3